MD Anderson's Therapeutics Discovery division, Orionis Biosciences launch Project Helios to advance novel small-molecule cancer medicines
E-Mail HOUSTON, BOSTON and GHENT, Belgium - The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions. Combining Orionis' unique high-throughput drug discovery technologies with the Therapeutics Discovery division's expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction ...